Mycolog-Ii

Pruritus Vulvae, Trichomonas Vaginitis, Pruritus Ani + 13 more

Treatment

15 Active Studies for Mycolog-Ii

What is Mycolog-Ii

Nystatin

The Generic name of this drug

Treatment Summary

Nystatin is a powerful antifungal drug used to treat infections caused by certain types of yeast and fungi, particularly Candida species. It is made from a strain of Streptomyces noursei bacteria and is similar to the drug amphotericin B. Nystatin is not suitable for intravenous use because of its toxicity, but it can be taken by mouth or applied topically to treat skin, mucous membrane, and gastrointestinal fungal infections.

Nystatin

is the brand name

Mycolog-Ii Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nystatin

Nystatin

1979

252

Effectiveness

How Mycolog-Ii Affects Patients

Nystatin is an antifungal medication used to treat yeast and yeast-like fungus infections. It works by damaging the cell membrane of the fungus, and has very little resistance. Nystatin doesn't work against bacteria, parasites, or viruses, and is only available in topical and oral forms, as it is too toxic to be used systemically.

How Mycolog-Ii works in the body

Nystatin is a drug that works by creating a hole in the membrane of fungal cells. This causes the cells to leak their contents, preventing them from functioning properly. Nystatin is selective for fungal cells because it binds better to the sterol found in their cell walls than it does to cholesterol, which is found in mammalian cells.

When to interrupt dosage

The measure of Mycolog-Ii is contingent upon the diagnosed disorder, including cutaneous candidiasis, Skin candida and corticosteroid-responsive dermatoses. The amount additionally varies according to the technique of delivery (e.g. Insert or Insert - Vaginal) depicted in the table below.

Condition

Dosage

Administration

Skin candida

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Anal candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Skin Diseases

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Oral

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Low; Birthweight

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Ani

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

cutaneous candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Urinary Tract Infection (UTI)

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candida albicans

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Vulvae

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Trichomonas Vaginitis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Invasive

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Yeast Infection

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Warnings

Mycolog-Ii Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nystatin may interact with Pulse Frequency

There are 20 known major drug interactions with Mycolog-Ii.

Common Mycolog-Ii Drug Interactions

Drug Name

Risk Level

Description

Revefenacin

Major

Nystatin may decrease the excretion rate of Revefenacin which could result in a higher serum level.

Ambrisentan

Minor

The excretion of Ambrisentan can be decreased when combined with Nystatin.

Asunaprevir

Minor

The excretion of Asunaprevir can be decreased when combined with Nystatin.

Atorvastatin

Minor

The excretion of Atorvastatin can be decreased when combined with Nystatin.

Atrasentan

Minor

The excretion of Atrasentan can be decreased when combined with Nystatin.

Mycolog-Ii Toxicity & Overdose Risk

The lowest toxic dose of nystatin in rats has been found to be 10g/kg. Taking too much nystatin can cause nausea and stomach upset, but no other serious side effects have been reported from taking doses larger than five million units per day.

image of a doctor in a lab doing drug, clinical research

Mycolog-Ii Novel Uses: Which Conditions Have a Clinical Trial Featuring Mycolog-Ii?

39 active studies are analyzing the potential of Mycolog-II to address Urinary Tract Infections (UTI), Yeast Infections and Pruritus Ani.

Condition

Clinical Trials

Trial Phases

Pruritus Ani

0 Actively Recruiting

Candida albicans

0 Actively Recruiting

Skin candida

0 Actively Recruiting

Anal candidiasis

0 Actively Recruiting

Candidiasis, Invasive

4 Actively Recruiting

Phase 3, Not Applicable

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Candidiasis, Oral

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Low; Birthweight

2 Actively Recruiting

Not Applicable

Skin Diseases

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Candidiasis

0 Actively Recruiting

Candidiasis, Vulvovaginal

2 Actively Recruiting

Not Applicable, Phase 3

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Pruritus Vulvae

0 Actively Recruiting

Candidiasis, Vulvovaginal

0 Actively Recruiting

Patient Q&A Section about mycolog-ii

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Mycolog II cream used for?

"This medication is used to treat fungal skin infections and it contains nystatin which is an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone which is an anti-inflammatory corticosteroid that works by reducing swelling, itching and redness."

Answered by AI

What is in Mycolog cream?

"Mycolog-II (Nystatin and Triamcinolone Acetonide Ointment) contains 100,000 USP nystatin units and 1 mg triamcinolone acetonide in each gram, in a protective ointment base of Plastibase® (Plasticized Hydrocarbon Gel), a polyethylene and mineral oil gel base."

Answered by AI

What is the generic name for Mycolog cream?

"Triamcinolone acetonide is a white to cream crystalline powder that is practically insoluble in water and very soluble in alcohol. It has a slight odor."

Answered by AI

What is triamcinolone nystatin cream used for?

"This medicine helps to treat skin conditions by reducing redness, swelling, and itchiness. It is also effective in treating fungal infections like Candida, and relieving the associated discomfort."

Answered by AI

Clinical Trials for Mycolog-Ii

Have you considered Mycolog-Ii clinical trials?

We made a collection of clinical trials featuring Mycolog-Ii, we think they might fit your search criteria.
Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

Phase 4
Recruiting

Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)

Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Phase 4
Recruiting

University of Missouri

Kevin M Klifto, DO, PharmD

Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Antifungal Therapy Duration for Candidemia in Children

120 - 18
All Sexes
Philadelphia, PA

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

Recruiting
Has No Placebo

Children's Hospital of Philadelphia (+17 Sites)

Brian Fisher, DO

Have you considered Mycolog-Ii clinical trials?

We made a collection of clinical trials featuring Mycolog-Ii, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Data Accountability + Doula Support for Maternal Health Disparities

12 - 99
Female
Chapel Hill, NC

This project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 39 prenatal practices across North Carolina. Practices have been randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for \~750-1,500 patients (up to 60,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.

Recruiting
Has No Placebo

University of North Carolina at Chapel Hill

Jennifer H Tang, MD, MSCR

Image of Houston Methodist Hospital - Texas Medical Center in Houston, United States.

Fosmanogepix for Candida Blood Infection

18+
All Sexes
Houston, TX

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

Phase 3
Recruiting

Houston Methodist Hospital - Texas Medical Center (+12 Sites)

Manuel Häckl, MD

Basilea Pharmaceutica

Have you considered Mycolog-Ii clinical trials?

We made a collection of clinical trials featuring Mycolog-Ii, we think they might fit your search criteria.
Go to Trials